OSU-T315 (1,3-regioisomer)
ILK-IN-2
CAS: 2070015-22-2
Molecular Formula: C30H30F3N5O
OSU-T315 (1,3-regioisomer) - Names and Identifiers
| Name | ILK-IN-2 |
| Synonyms | OSU-T315 ILK-IN-2 OSU-T315 (ILK-IN-1) OSU-T315 (1,3-regioisomer) OSU-T315 (1,5-regioisomer) 1H-Pyrazole-5-propanamide, N-methyl-1-[4-(1-piperazinyl)phenyl]-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- N-Methyl-3-(1-(4-(piperazin-1-yl)phenyl)-3-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl)propanamide |
| CAS | 2070015-22-2 |
OSU-T315 (1,3-regioisomer) - Physico-chemical Properties
| Molecular Formula | C30H30F3N5O |
| Molar Mass | 533.59 |
| Solubility | DMSO : 50 mg/mL (93.70 mM);H2O : < 0.1 mg/mL (insoluble) |
| Storage Condition | 2-8°C(protect from light) |
OSU-T315 (1,3-regioisomer) - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.874 ml | 9.37 ml | 18.741 ml |
| 5 mM | 0.375 ml | 1.874 ml | 3.748 ml |
| 10 mM | 0.187 ml | 0.937 ml | 1.874 ml |
| 5 mM | 0.037 ml | 0.187 ml | 0.375 ml |
Last Update：2024-01-02 23:10:35
OSU-T315 (1,3-regioisomer) - Reference Information
| biological activity | OSU-T315 (ILK-IN-2) is a potent inhibitor of Integrin-Linked Kinase (ILK), the IC50 value was 0.6 μm. OSU-T315 induces autophagy and apoptosis, both of which are essential for its antiproliferative activity. OSU-T315 has anti-tumor activity. |
| Target | Value |
| ILK (Cell-free assay) | 0.6 μM |
| Cell Line: | PC-3 cells; MDA-MB-231 cells Prostate cancer cells: LNCaP, PC-3; breast cancer cells: MDA-MB-231, MDA-MB-468, SKBR3, MCF-7; PrEC and MEC cells PC-3 cells |
| Concentration: | 1 μM, 2 μM, 3 μM, 4 μM; 0.5 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM 0-5 μM 1 μM, 2 μM, 3 μM, 4 μM |
| Incubation Time: | 24 hours 24 hours 24 hours |
| Result: | Exhibited a dose-dependent decreasing effect on the phosphorylation of pS6, ERKs, and p38 in PC-3 cells and MDA-MB-231 cells. Suppressed cancer cells viability in breast and prostate cancer cells (IC (50), 1-2.5μM). Induced accumulation of LC3-II and PARP cleavage. Resulted in suppression of tumor growth relative to the vehicle control after 35 days of treatment (48% and 62% suppression for 25 and 50 mg/kg, respectively). |
| Animal Model: | Male NCr athymic nude mice with PC-3 tumor xenografts |
| Dosage: | 25 mg/kg; 50 mg/kg |
| Administration: | Oral gavage; single daily; 35 days |
Last Update：2024-04-09 20:52:54
Supplier List
Spot supply
Product Name: ILK-IN-2 Visit Supplier Webpage Request for quotationCAS: 2070015-22-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: ILK-IN-2 Visit Supplier Webpage Request for quotationCAS: 2070015-22-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History